Andra AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.44M | Sell |
27,400
-61,700
| -69% | -$7.76M | 0.05% | 306 |
|
|
2025
Q1 | $9.85M | Sell |
89,100
-11,200
| -11% | -$1.24M | 0.16% | 216 |
|
|
2024
Q4 | $13.7M | Sell |
100,300
-77,600
| -44% | -$10.6M | 0.22% | 179 |
|
|
2024
Q3 | $20.5M | Buy |
177,900
+16,600
| +10% | +$1.91M | 0.3% | 108 |
|
|
2024
Q2 | $22.2M | Buy |
161,300
+86,900
| +117% | +$12M | 0.37% | 85 |
|
|
2024
Q1 | $10.3M | Buy |
74,400
+1,600
| +2% | +$221K | 0.18% | 181 |
|
|
2023
Q4 | $9.59M | Buy |
72,800
+18,200
| +33% | +$2.4M | 0.51% | 67 |
|
|
2023
Q3 | $6.14M | Sell |
54,600
-13,300
| -20% | -$1.5M | 0.36% | 126 |
|
|
2023
Q2 | $6.4M | Sell |
67,900
-33,500
| -33% | -$3.16M | 0.16% | 294 |
|
|
2023
Q1 | $10.3M | Buy |
101,400
+8,700
| +9% | +$881K | 0.27% | 108 |
|
|
2022
Q4 | $11.1M | Buy |
92,700
+34,000
| +58% | +$4.06M | 0.34% | 38 |
|
|
2022
Q3 | $6.24M | Buy |
58,700
+11,800
| +25% | +$1.25M | 0.2% | 212 |
|
|
2022
Q2 | $4.57M | Buy |
+46,900
| New | +$4.57M | 0.13% | 357 |
|
|
2021
Q4 | $5.85M | Buy |
68,700
+17,200
| +33% | +$1.46M | 0.12% | 382 |
|
|
2021
Q3 | $4.94M | Sell |
51,500
-4,300
| -8% | -$412K | 0.1% | 427 |
|
|
2021
Q2 | $5.43M | Buy |
55,800
+44,700
| +403% | +$4.35M | 0.11% | 422 |
|
|
2021
Q1 | $1.08M | Sell |
11,100
-5,000
| -31% | -$486K | 0.02% | 562 |
|
|
2020
Q4 | $1.54M | Buy |
16,100
+8,500
| +112% | +$815K | 0.03% | 571 |
|
|
2020
Q3 | $731K | Sell |
7,600
-23,400
| -75% | -$2.25M | 0.02% | 604 |
|
|
2020
Q2 | $3.78M | Buy |
31,000
+4,300
| +16% | +$525K | 0.11% | 481 |
|
|
2020
Q1 | $2.31M | Buy |
26,700
+3,700
| +16% | +$320K | 0.08% | 569 |
|
|
2019
Q4 | $2.47M | Buy |
+23,000
| New | +$2.47M | 0.07% | 594 |
|